“武当二号金银花”叶中芦丁和金丝桃苷的含量测定

摘 要 目的：采用HPLC DAD法测定“武当二号金银花”叶中芦丁和金丝桃苷的含量。方法: 色谱柱为Fortis Xi Phenyl柱 (250 mm×4.6 mm,5 μm),流动相为乙腈 0.5%冰醋酸水溶液,梯度洗脱,流速为0.9 ml·min^-1,检测波长为354 nm,柱温为30℃。结果:芦丁及金丝桃苷分别在9.00～90.00 μg·ml^-1、16.35～163.50 μg·ml^-1浓度范围内与峰面积呈良好的线性关系 (r=0.999 5),平均回收率分别为99.70%（RSD=1.96%）、99.30%（RSD=1.95%）。结论:该法简便、准确、重现性好、专属性强,可用于“武当二号金银花”叶中芦丁和金丝桃苷的含量测定。     

HPLC法测定追风舒筋活血片中马钱子碱、士的宁的含量

摘 要 目的： 建立追风舒筋活血片中马钱子碱、士的宁的含量测定方法。方法: 应用高效液相色谱法测定,色谱柱为Agilent SB C₁₈柱(250 mm×4.6 mm,5 μm),以乙腈 0.01 mol·L^-1庚烷磺酸钠与0.02 mol·L^-1磷酸二氢钾等量混合溶液（用10%磷酸调节pH至2.8）（21∶79）为流动相,检测波长为260 nm,流速为1.0 ml·min^-1,柱温为35℃,进样量为10 μl。结果: 马钱子碱和士的宁的线性范围分别为0. 011 0~0.219 6 mg·ml^-1 (r=0.999 4)、0.010 1~0.202 8 mg·ml^-1 (r=0.999 7);平均加样回收率分别为98.24%(RSD=1.54%)、97.92%(RSD=1.49%)(n=6) 。结论:该方法简便易行、准确、重复性好,可用于追风舒筋活血片的质量控制。     

九节茶药材中鞣质含量测定方法的改进

摘 要 目的：对九节茶药材中鞣质含量的紫外分光光度测定方法加以改进。方法: 对中国药典鞣质含量测定方法（干酪素法）进行改进,供试品溶液的制备采用加热回流法或加热超声法代替药典中的静置过夜法,并将干酪素粒度明确为极细粉,由此建立了九节茶药材中的鞣质含量测定方法。结果:方法改进后,没食子酸在1.002~10.016 μg·ml^-1范围内与其吸光度呈良好的线性关系（r=0.999 4）,九节茶药材鞣质平均回收率为97.81%,RSD为1.89%（n=6）。结论:该测定方法解决了原方法中重复性差、准确度低、操作用时长的问题,提高了测定结果的准确度和检测效率。     

HPLC波长切换法测定氨咖黄敏胶囊4个成分的含量

摘 要 目的： 建立HPLC波长切换法同时测定氨咖黄敏胶囊中4个成分的含量。方法: 采用Agilent ZORBAX SB C₁₈色谱柱（250 mm×4.6 mm,5 μm）,以乙腈（A）-甲醇（B）-磷酸二氢铵溶液（取0.1 mol·L^-1磷酸二氢铵溶液1 000 ml ,加磷酸1 ml,混匀）（C）为流动相,梯度洗脱,流速1.0 ml·min^-1,柱温 35℃,变换波长时间为（0～9 min ：225 nm;9～38 min ：450 nm）。结果: 采用HPLC波长切换法测定氨咖黄敏胶囊4个成分的含量,线性范围分别为：对乙酰氨基酚24.680～394.900 μg·ml^-1（r=0.999 9）,马来酸氯苯那敏0.201～3.214 μg·ml^-1（r=0.999 9）,咖啡因1.129～18.070 μg·ml^-1（r=0.999 9）,胆红素0.010～0.165 μg·ml^-1（r=0.999 8）;平均回收率分别为：99.25% (RSD=0.46%), 99.29% (RSD=0.32%),99.49% (RSD=0.48%)及99.75% (RSD=0.55%)（n=6）。结论:该法简单,灵敏,准确,重复性好,可用于氨咖黄敏胶囊的含量测定。     

HPLC法测定吲哚美辛呋喃唑酮栓中两组分的含量

摘 要 目的：建立同时测定吲哚美辛呋喃唑酮栓中两组分含量的HPLC法。方法: 采用XTerra RP18色谱柱(250 mm×4.6 mm,5 μm),以甲醇为流动相A,0.01 mol·K^-1磷酸二氢钾溶液 三乙胺(100〖KG*9〗∶〖KG-*2〗0.02)为流动相B,梯度洗脱,流速1.0 ml·min^-1,柱温30 ℃,检测波长263 nm,进样量10 μl。结果: 吲哚美辛呋喃唑酮栓中呋喃唑酮和吲哚美辛的分离度符合要求;线性范围分别为5.12~81.87 μg·ml^-1 (r=1.000 0)和3.78~60.45 μg·ml^-1 (r=1.000 0);平均回收率分别为99.6% (RSD=1.5%,n=6)和100.3% (RSD=1.6%,n=6);定量限分别为0.02 μg·ml^-1和0.05 μg·ml^-1。结论:该法经方法学验证,适用于吲哚美辛呋喃唑酮栓的质量评价。     

UPLC法同时测定消积化虫散中3种成分的含量

摘 要 目的：建立UPLC同时测定消积化虫散中橙皮苷、和厚朴酚、厚朴酚3种成分含量的分析方法。方法: 采用Thermo Accucore C18（150 mm×4.6 mm, 2.6 μm）,以甲醇 0.5%冰醋酸水溶液为流动相进行梯度洗脱,流速：0.7 ml·min^-1 ,柱温：30℃,检测波长：283 nm,进样量：2 μl。结果: 橙皮苷、和厚朴酚、厚朴酚分别在4.707~28.242 mg·ml^-1 (r=0.999 4)、5.085~30.510 mg·ml^-1 (r=0.999 7)、10.651~63.908 mg·ml^-1 (r=0.999 5)浓度范围内线性关系良好,平均加样回收率分别为101.2%,104.8%,99.4%,RSD分别为1.11%,1.68%,1.49%（n=6）。结论: 本试验为消积化虫散的质量评价提供了简单、有效的方法。     

离子色谱法测定枸橼酸氢钾钠颗粒中多种成分的含量

摘 要 目的：建立离子色谱法测定枸橼酸氢钾钠颗粒中钠、钾和枸橼酸含量的方法。方法: 钾和钠的色谱条件：采用Dionex IonPac CS12A色谱柱（250 mm×4.6 mm,5 μm）,流动相为0.02 mol·L^-1甲烷磺酸溶液,流速为1.0 ml·min^-1,抑制器为CSRS 300,抑制电流为59 mA,采用抑制型电导检测器,进样量为25 μl。枸橼酸的色谱条件：采用Dionex HPICE AS1离子排斥色谱柱（250 mm×9.0 mm,7.5 μm）,流动相为0.015 mol·L^-1硫酸溶液,流速为0.6 ml·min^-1,检测波长为220 nm,进样量为10 μl。结果: 钠的线性范围为0.82～82.49 μg·ml^-1（r=0.999 9）,平均回收率为98.9%,RSD为0.55% （n=9）;钾的线性范围为1.38～137.89 μg·ml^-1（r=1.000 0）,平均回收率为100.5%,RSD为0.53%（n=9）;枸橼酸的线性范围为0.021～10.600 mg·ml^-1（r=1.000 0）,平均回收率为99.1%,RSD为0.54%（n=9）。结论:本方法简便、快速、准确,可用于枸橼酸氢钾钠颗粒的质量控制。     

HPLC测定新舒通胶囊中血竭素与亚油酸含量

摘 要 目的： 建立测定新舒通胶囊中血竭素与亚油酸含量的高效液相色谱法。方法: 采用高效液相色谱法,菲罗门Kinetex C₁₈色谱柱(100 mm×4.6 mm,2.6 μm),以乙腈为流动相A,0.1%磷酸溶液为流动相B,进行梯度洗脱,检测波长为210 nm,柱温为35℃,流速为1.0 ml·min^-1。结果: 血竭素进样量在79.22×10^-6～15.84×10^-4 mg,亚油酸在89.56×10^-5～17.91×10^-3 mg范围内与峰面积呈良好线性关系（r₁=0.999 9,血竭素;r2=0.999 9,亚油酸）,血竭素加样回收率为99.9%、RSD为1.0% (n=6),亚油酸加样回收率为98.3％、RSD为1.4％(n=6)。结论: 该方法快速、灵敏、准确,可作为新舒通胶囊的含量测定方法。     

HPLC法测定二甲氨基阿格拉宾盐酸盐的含量

摘 要 目的: 建立二甲氨基阿格拉宾盐酸盐的含量测定方法。方法: 色谱柱为氨基柱（250 mm×4.6 mm,5 μm）,以乙腈 0.01 mol·L^-1磷酸铵（用磷酸调节pH至6.5）（60∶〖KG-*2〗40）为流动相,流速为1.0 ml·min^-1,检测波长为210 nm,柱温30 ℃,进样量20 μl。结果:二甲氨基阿格拉宾盐酸盐与阿格拉宾及其他杂质之间能够达到很好分离;二甲氨基阿格拉宾盐酸盐在1.0～6.0 mg·ml^-1浓度范围内线性关系良好（r=0.999 9),平均加样回收率为99.07%,RSD为0.76%（n=9）。结论:该法测定二甲氨基阿格拉宾盐酸盐含量,简便、准确、重复性好。     

HPLC法同时测定蛇胆追风丸中阿魏酸、蛇床子素的含量

摘 要 目的： 采用HPLC法同时测定蛇胆追风丸中阿魏酸、蛇床子素的含量。方法: 采用Phenomenex Synergi C₁₈(250 mm×4.6 mm,4 μm)色谱柱,流动相为甲醇 0.1%磷酸,梯度洗脱,检测波长为322 nm,流速为1.0 ml·min^-1。结果: 阿魏酸、蛇床子素线性范围分别为1.244～14.928 μg·ml^-1(r＝0.999 9)、5.004～25.020 μg·ml^-1(r＝0.999 8),平均加样回收率分别为98.3%(RSD=1.4%,n=6)、98.2%(RSD=1.6%,n=6)。结论: 该方法操作简便,结果准确可靠,可作为蛇胆追风丸中阿魏酸、蛇床子素的含量测定方法。     

Efficacy of gut lavage,hemodialysis, and hemoperfusion in the therapy of paraquat or diquat intoxication

Clinical and in vitro investigations were carried out to test the efficacy of gut lavage, hemodialysis, and hemoperfusion in the treatment of poisoning with paraquat or diquat. In a patient suffering from diquat intoxication 130 times more diquat was removed by gut lavage 30 h after ingestion than was removed by complete aspiration of the gastric contents.Determination of in vitro clearances for paraquat and diquat by hemodialysis showed that, at serum concentrations of 1–2 ppm, such as are frequently encountered in poisoning in man, toxicologically relevant quantities of herbicide cannot be removed from the body. At a concentration of 20 ppm, on the other hand, hemodialysis proved to be effective, the clearance being 70 ml/min at a blood flow rate of 100 ml/min. The efficacy of hemoperfusion with coated activated charcoal was on the whole better. Especially at concentrations around 1–2 ppm, the clearance values for hemoperfusion were some 5–7 times higher than those for hemodialysis.In a patient suffering from paraquat poisoning, both hemodialysis as well as hemoperfusion were carried out. The in vitro results could be confirmed: At serum concentrations of paraquat less than 1 ppm no clearance could be obtained by hemodialysis while by hemoperfusion with activated charcoal quite high clearance values were measured and the serum level dropped down to zero.

---

Zusammenfassung Klinische Untersuchungen und Laboratoriumsversuche wurden durchgeführt, um die Wirksamkeit von Darmspülung, Hämodialyse und Hämoperfusion bei Paraquat- und Deiquat-Vergiftungen zu prüfen.Bei einem Patienten wurde 30 Std nach Deiquat-Aufnahme durch Darmspülung 130mal mehr Deiquat entfernt als durch vollständige Aspiration des Mageninhaltes. In vitro-Versuche ergaben, daß bei Blutserumkonzentrationen von 1–2 ppm, die bei Vergiftungen oft gemessen werden, durch Hämodialyse keine toxikologisch relevanten Paraquat- oder Deiquat-Mengen entfernt werden können. Dagegen erwies sich die Hämodialyse bei 20 ppm und einer Blutumlaufgeschwindigkeit von 100 ml/min mit einer Clearance von 70 ml/min als wirksam. Die Hämoperfusion mit beschicheter Aktivkohle war in diesen Versuchen aber eindeutig überlegen, denn insbesondere bei Konzentrationen um 1–2 ppm waren die Clearance-Werte 5–7mal höher als bei der Hämodialyse.Die in vitro-Ergebnisse wurden bei einem Patienten mit einer Paraquat-Vergiftung bestätigt: Bei Konzentrationen unter 1 ppm war die Hämodialyse wirkungslos, während durch Hämoperfusion relativ hohe Clearance-Werte erreicht wurden, so daß der Serumspiegel rasch unter die Nachweisgrenze abfiel.

     

Aquatic Insects and Trace Metals: Bioavailability,Bioaccumulation, and Toxicity

Abstract

The uptake of metals from food and water sources by insects is thought to be additive. For a given metal, the proportions taken up from water and food will depend both on the bioavailable concentration of the metal associated with each source and the mechanism and rate by which the metal enters the insect. Attempts to correlate insect trace metal concentrations with the trophic level of insects should be made with a knowledge of the feeding relationships of the individual taxa concerned. Pathways for the uptake of essential metals, such as copper and zinc, exist at the cellular level, and other nonessential metals, such as cadmium, also appear to enter via these routes. Within cells, trace metals can be bound to proteins or stored in granules. The internal distribution of metals among body tissues is very heterogeneous, and distribution patterns tend to be both metal and taxon specific. Trace metals associated with insects can be both bound on the surface of their chitinous exoskeleton and incorporated into body tissues. The quantities of trace meals accumulated by an individual reflect the net balance between the rate of metal influx from both dissolved and particulate sources and the rate of metal efflux from the organism. The toxicity of metals has been demonstrated at all levels of biological organization: cell, tissue, individual, population, and community. Much of the literature pertaining to the toxic effects of metals on aquatic insects is based on laboratory observations and, as such, it is difficult to extrapolate the data to insects in nature. The few experimental studies in nature suggest that trace metal contaminants can affect both the distribution and the abundance of aquatic insects. Insects have a largely unexploited potential as biomonitors of metal contamination in nature. A better understanding of the physico-chemical and biological mechanisms mediating trace metal bioavailability and exchange will facilitate the development of general predictive models relating trace metal concentrations in insects to those in their environment. Such models will facilitate the use of insects as contaminant biomonitors.     

Alzheimer’s disease – current trends in basic and clinical research. Highlights from the 16th ECNP

Advances in the molecular biological knowledge of neuronal nicotinic acetylcholine receptors (nAChRs) have led to a growing interest by the pharmaceutical industry in the development of novel compounds that selectively modulate nAChR function. The ability of (-)-nicotine, an activator of nAChRs, to enhance attentional aspects of cognition in animals and humans, to exert neuroprotective and anxiolytic-like effects, and presumably to mediate the negative correlation between smoking and Alzheimer's (and Parkinson's) Disease, has focused interest on the potential therapeutic utility of modulators of nAChR function for treatment of some of the deficits associated with these progressive, neurodegenerative conditions. Numerous compounds are known which activate nAChRs and which might serve as lead compounds toward the development of such agents. The pharmacologic diversity of neuronal nAChR subtypes suggests the possibility of developing selective compounds which would have more favourable side-effect profiles than existing agents. This broader class of agents, collectively called cholinergic channel modulators (ChCMs), is anticipated to encompass compounds which would have more favourable side-effect profiles than existing agents, which generally exhibit low selectivity. This selectivity may be achieved by preferentially activating some subtypes of nAChRs (i.e., Cholinergic Channel Activators, ChCAs) or inhibiting the function of other subtypes (Cholinergic Channel Inhibitors, ChCIs). An overview of the biology of nAChRs and the rationale for the use of ChCMs for the treatment of dementia related to neurodegenerative diseases are presented, followed by a discussion of lead compounds and compounds under consideration for clinical evaluation.     

2-(Acetoxyphenyl)-(Z)-styryl sulfides as cyclooxygenase inhibitors

2-(Acetoxyphenyl)-(Z)-styryl sulfides are described as selective cyclooxygenase-2 (COX-2) inhibitors, useful for treating inflammation and COX-2-mediated disorders including neoplasia. 2-(Acetoxyphenyl)-(Z)-styryl sulfide is claimed to be the most potent COX inhibitor in the series with a COX-2 selectivity ratio of 33. This compound is also claimed to be superior to celecoxib (Celebrex^®, Pfizer) in inhibiting cell growth of colorectal carcinoma cells. In this evaluation, the COX inhibitory activity of this compound is compared to that previously disclosed for diarylheterocycles and 2-(acetoxyphenyl)alkyl sulfides. The validity of the DLD-1 cell line in the growth inhibition studies is questioned based on recent literature reports indicating the lack of COX-2 expression in this cell line.     

Sleep-disordered breathing with chronic opioid use

Chronic opioid use for pain relief or as substitution therapy for illicit drug abuse is prevalent in our societies. In the US, retail distribution of methadone and oxycodone has increased by 824 and 660%, respectively, between 1997 and 2003. μ-Opioids depress respiration and deaths related to illicit and non illicit chronic opioid use are not uncommon. Since 2001 there has been an emerging literature that suggests that chronic opioid use is related to central sleep apnoea of both periodic and non-periodic breathing types, and occurs in ～ 30% of these subjects. The clinical significance of these sleep-related abnormalities are unknown. This review addresses the present knowledge of control of ventilation mechanisms during wakefulness and sleep, the effects of opioids on ventilatory control mechanisms, the sleep-disordered breathing found with chronic opioid use and a discussion regarding the future research directions in this area.     

Drug targets for cognitive enhancement in neuropsychiatric disorders

The investigation of novel drug targets for treating cognitive impairments associated with neurological and psychiatric disorders remains a primary focus of study in central nervous system (CNS) research. Many promising new therapies are progressing through preclinical and clinical development, and offer the potential of improved treatment options for neurodegenerative diseases such as Alzheimer's disease (AD) as well as other disorders that have not been particularly well treated to date like the cognitive impairments associated with schizophrenia (CIAS). Among targets under investigation, cholinergic receptors have received much attention with several nicotinic agonists (α7 and α4β2) actively in clinical trials for the treatment of AD, CIAS and attention deficit hyperactivity disorder (ADHD). Both glutamatergic and serotonergic (5-HT) agonists and antagonists have profound effects on neurotransmission and improve cognitive function in preclinical experiments with animals; some of these compounds are now in proof-of-concept studies in humans. Several histamine H3 receptor antagonists are in clinical development not only for cognitive enhancement, but also for the treatment of narcolepsy and cognitive deficits due to sleep deprivation because of their expression in brain sleep centers. Compounds that dampen inhibitory tone (e.g., GABA_A α5 inverse agonists) or elevate excitatory tone (e.g., glycine transporter inhibitors) offer novel approaches for treating diseases such as schizophrenia, AD and Down syndrome. In addition to cell surface receptors, intracellular drug targets such as the phosphodiesterases (PDEs) are known to impact signaling pathways that affect long-term memory formation and working memory. Overall, there is a genuine need to treat cognitive deficits associated with many neuropsychiatric conditions as well as an increasingly aging population.